Wu et al. have shown that Sevoflurane suppresses EMT in breast cancer cells by regulating miR-139–5p/ARF6, while Liu et al. demonstrated that a standard clinical concentration of Sevoflurane inhibits breast cancer cell proliferation through the upregulation of microRNA-203 [8, 30]. This evidence concerns the gene ARF6 and breast carcinoma.